1. Home
  2. OPT vs ECX Comparison

OPT vs ECX Comparison

Compare OPT & ECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OPT
  • ECX
  • Stock Information
  • Founded
  • OPT 1984
  • ECX 2017
  • Country
  • OPT Australia
  • ECX China
  • Employees
  • OPT N/A
  • ECX N/A
  • Industry
  • OPT Biotechnology: Biological Products (No Diagnostic Substances)
  • ECX EDP Services
  • Sector
  • OPT Health Care
  • ECX Technology
  • Exchange
  • OPT Nasdaq
  • ECX Nasdaq
  • Market Cap
  • OPT 574.0M
  • ECX 584.9M
  • IPO Year
  • OPT 2020
  • ECX N/A
  • Fundamental
  • Price
  • OPT $3.90
  • ECX $1.91
  • Analyst Decision
  • OPT Strong Buy
  • ECX
  • Analyst Count
  • OPT 1
  • ECX 0
  • Target Price
  • OPT $12.00
  • ECX N/A
  • AVG Volume (30 Days)
  • OPT 18.3K
  • ECX 1.6M
  • Earning Date
  • OPT 02-26-2025
  • ECX 02-26-2025
  • Dividend Yield
  • OPT N/A
  • ECX N/A
  • EPS Growth
  • OPT N/A
  • ECX N/A
  • EPS
  • OPT N/A
  • ECX N/A
  • Revenue
  • OPT $261,859.00
  • ECX $778,608,168.00
  • Revenue This Year
  • OPT N/A
  • ECX $20.12
  • Revenue Next Year
  • OPT $46,864.26
  • ECX $32.70
  • P/E Ratio
  • OPT N/A
  • ECX N/A
  • Revenue Growth
  • OPT N/A
  • ECX 25.45
  • 52 Week Low
  • OPT $1.79
  • ECX $0.96
  • 52 Week High
  • OPT $5.45
  • ECX $3.09
  • Technical
  • Relative Strength Index (RSI)
  • OPT 56.41
  • ECX 47.06
  • Support Level
  • OPT $3.59
  • ECX $1.78
  • Resistance Level
  • OPT $3.90
  • ECX $2.25
  • Average True Range (ATR)
  • OPT 0.24
  • ECX 0.14
  • MACD
  • OPT 0.02
  • ECX -0.02
  • Stochastic Oscillator
  • OPT 74.11
  • ECX 27.35

About OPT Opthea Limited

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.

About ECX ECARX Holdings Inc. Ordinary shares

ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services primarily in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.

Share on Social Networks: